Tag - Aravive

HCW starts Aravive at buy; PT $18

H.C. Wainwright launched coverage of Aravive (NASDAQ:ARAV) with a “buy” rating and $18 price target. The stock closed at $6.38 on Oct. 9. The company’s lead asset is AVB-500, an anti-GAS6 selective decoy, used to...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.